🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Population differences in the associations between chromosomal abnormalities and overall survival of multiple myeloma [Jan 31, 2025] Bei Wang et al. Blood Neoplasia ashpublications.org/bloodneoplasia… #mmsm #PrecisionMedicine #cancerdisparities

Our open access article “BCMA-directed CAR T-cell Therapy in patients with multiple myeloma and CNS involvement” is now available online (link below). #mmsm #cart Krina Patel authors.elsevier.com/sd/article/S24…

🧐Our DEPEND trial is out! Neoadjuvant nivo/chemo followed by response-stratified CRT in HPV-negative stage IVa/b HNSCC. UChicagoCancerCenter University of Chicago Hematology/Oncology Aditya Juloori Pearson Lab Nishant Agrawal Evgeny Izumchenko Everett Vokes jamanetwork.com/journals/jamao…

It's important for patients with myeloma to be familiar with myeloma tests and allows for better engagement in their care! Come join us!

We need to adjust IMWG response criteria so that light chain escape meets biochemical progression of disease. Patients with measurable M spike at diagnosis cannot meet biochemical progression criteria on trial by light chains (a scenario we see commonly enough). One of the

Another challenge with trial enrollment. Most trials restrict enrollment to patients who have an M spike of 1 g/dL or free light chains of at least 10 mg/dL to enable full response adjudication. But patients with ‘oligosecretory’ disease are excluded. This becomes especially

Combination strategies - esp with Dara - performed well, though might be because of differences in prior treatment exposure. I still prefer to use venetoclax in combinations and Dara-Ven is my favorite combo.